INS and Insulin resistance: Currently, patients with insulin resistance and islet dysfunction are treated with insulin sensitizers and secretagogues, which work mainly by improving glucose disposal via skeletal muscle and suppressing hepatic gluconeogenesis, and by stimulating pancreatic beta-cell insulin secretion, respectively [12].